MKGAF Merck Kgaa
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer or multiple sclerosis, infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as carcinoma of the head and neck; prescription drugs for allergen immunotherapy; and fertility treatments. The company also provides life science products and services for the research and applied laboratory applications, as well as for formulating, purifying, manufacturing, and quality-assuring drug therapies of chemical and biological origin; and specialty chemicals, such as liquid crystals and OLED materials for use in displays, materials for integrated circuits, effect pigments for coatings and color cosmetics, as well as functional materials for energy solutions. It has strategic alliances with Pfizer Inc. and GlaxoSmithKline plc; agreement with Intrexon Corporation and Avillion LLP; collaboration with F-star Delta Ltd.; an agreement IAVI and Serum Institute of India Pvt. Ltd. to develop SARS-CoV-2 neutralizing monoclonal antibodies; and collaboration with Iktos for new drug design. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.
Note: This is not a U.S. company, but they cross-list their shares on the U.S. over-the-counter market - see the related symbol GF:MRK.
$217.82 Pink
As of 01/21/2022 OTCMarkets
Security Information
Category1: US Equity
Category2: Common stocks
Category3: Large cap
GICS sector: Health Care
Industry: Drug Manufacturers-Specialty &
Index country: Germany
Country of incorporation:
IPO date: 11/30/2018
Outstanding shares: 129,242,250
Average volume: 369
Market cap: $28,245,893,738
Current dividend yield: 0.78%
Sedol:
Valuation (See tab for details)
PE ratio: 10.50
PB ratio: 4.61
PS ratio: 1.31
Return on equity: 13.05%
Net income %: 14.10%